Bio-Techne Corporation (TECH) Fair Value 2026

TECH · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.3 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, Bio-Techne Corporation (TECH) trades at $72.47, versus a $11.01 median fair value across its 11 active models — 84.8% below the current price. QOC: 8.3/10. Value Trap Risk: 18/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $20.44.

Key Facts

Ticker
TECH
Price
$72.47
Quality Score
8.3/10
Value Trap Risk
18/100
Models Active
11/13
Last Updated
Strength: Quality Score of 8.3/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is Bio-Techne Corporation (TECH) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Bio-Techne Corporation (TECH) appears overvalued as of : the median of 11 independent fair value estimates is $11.01, 84.8% below the current price of $72.47. Estimates range from $2.34 to $23.89. TECH scores 8.3/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. TECH’s -84.8% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bio-Techne Corporation Stock in 2026? →

What Fair Value Does Each Model Give TECH?

11 Intrinsic Value Models vs. Current Price ($72.47)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $20.44 -71.8%
Intrinsic · High Conviction
 $11.01 -84.8%
Ensemble · Medium Conviction
 $13.76 -81.0%
Scenario · High Conviction
 $22.09 -69.5%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is TECH's Fair Value Range?

Spread across 11 independent models · $2.34 to $23.89

CirclFi's 11 active models place Bio-Techne Corporation (TECH) between $2.34 and $23.89 per share, a spread of 196% of the median. The median of that range — $11.01 — is the fair value CirclFi publishes for TECH, against a current price of $72.47.

Low · Sentiment SOTPHigh · RCMH-DCF
$2.34median $11.01$23.89
Where the range comes from
Most bearish modelSentiment SOTP$2.34
Most bullish modelRCMH-DCF$23.89
Model agreement0 bullish · 11 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TECH. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TECH, not a CirclFi price target. How each model works →

What Is Bio-Techne Corporation (TECH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bio-Techne Corporation's intrinsic value is estimated at $11.01. Trading at its current price of $72.47, the valuation engine raises significant caution: 11 of 11 models flag downside risk, projecting a median implied return of -84.8%. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About TECH?

11 of 13 models are currently active for TECH. All 11 active models suggest the stock trades above fair value. Taken together, their median fair value for TECH is $11.01 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $20.44 on its own, implying -71.8% downside from the current price. See which stocks rank higher →

How Does TECH Rank in Biotechnology?

Among 620 Biotechnology stocks, TECH ranks #22 by Quality of Company score. CirclFi's QOC score of 8.3/10 evaluates 32 fundamental signals. A score of 8.3 places TECH in the top tier.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Bio-Techne Corporation, metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is TECH a Value Trap?

CirclFi's Value Trap algorithm assigns TECH a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Bio-Techne Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Bio-Techne Corporation scores 8.3 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

Models cluster within a tight range (+29.7% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TECH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TECH's 11 active models, average confidence is 56%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bio-Techne Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

RIGLRigel Pharmaceuticals, Inc.QOC 8.4ACADACADIA Pharmaceuticals Inc.QOC 8.3CORTCorcept Therapeutics IncorporatedQOC 8.5MNKDMannKind CorporationQOC 8.3REGNRegeneron Pharmaceuticals, Inc.QOC 8.5TBPHTheravance Biopharma, Inc.QOC 8.2XLOXilio Therapeutics, Inc.QOC 5.8ARTVArtiva Biotherapeutics, Inc.QOC 4.9INKTMiNK Therapeutics, Inc.QOC 4.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: RIGL · ACAD · CORT · MNKD · REGN · TBPH · XLO · ARTV · INKT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TECH?

7 companies across all industries closest to TECH’s Quality of Company score of 8.3/10.

MCDMcDonald's CorporationQOC 8.3ORCLOracle CorporationQOC 8.3TIMBTIM S.A.QOC 8.3KEKimball Electronics, Inc.QOC 8.3OSWOneSpaWorld Holdings LimitedQOC 8.3FULTFulton Financial CorporationQOC 8.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MCD · ORCL · TIMB · KE · OSW · FULT · NVDA

Where Does TECH Sit in CirclFi's Biotechnology Rankings?

TECH is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Bio-Techne Corporation’s Valuation?

What is Bio-Techne Corporation's intrinsic value in 2026?

CirclFi puts Bio-Techne Corporation (TECH)'s intrinsic value at $11.01 — the median of 11 independent model estimates as of 2026-08-27, ranging from $2.34 to $23.89. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $20.44 on its own. The Quality of Company score is 8.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TECH overvalued or undervalued right now?

At $72.47, 0 of 11 active models suggest TECH may be undervalued, while 11 indicate potential overvaluation. The median of all 11 fair value estimates is $11.01, 84.8% below the current price of $72.47 — a consensus view that TECH is overvalued. The assessment depends on which methodology best fits Bio-Techne Corporation's business model in Biotechnology.

What does a Quality of Company score of 8.3 mean for TECH?

Bio-Techne Corporation's QOC of 8.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TECH?

CirclFi analyzes TECH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TECH?

Of the 11 models currently active on TECH, RCMH-DCF is the most bullish at $23.89 per share, and Sentiment SOTP is the most bearish at $2.34. CirclFi's published fair value for TECH is the median of that range, $11.01, not either extreme. The gap between the two ends equals 196% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TECH a value trap in 2026?

Bio-Techne Corporation's Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Bio-Techne Corporation (TECH) has a median fair value of $11.01 — 84.8% below the current price of $72.47 — as of 2026-08-27.” Source: circlfi.com/stock/TECH/ · Methodology
Primary sources for this TECH valuation
  • Financial statements: Bio-Techne Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000842023) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TECH as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on TECH.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for TECH Unlock All 11 — $39/mo